BioAge Labs, Inc. (BIOA)
Summary
BioAge: CV Risk Data Due H2 A Major Catalyst After Rival's Data Causes Sell-Off
BioAge Labs remains a buy despite a >40% stock drop, as the recent sell-off appears overblown given competitive Phase 1 data for BGE-102. BGE-102, a best-in-class NLRP3 inhibitor, achieved up to 98% IL-1β suppression and 86% median hsCRP reduction, with Phase 2 topline data expected in H2 2026. BIOA's diversified pipeline includes ophthalmology and apelin-APJ pathway programs, plus partnerships with Novartis and Eli Lilly, supporting long-term optionality.
BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates
BioAge Labs, Inc. (BIOA) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to a loss of $0.6 per share a year ago.
BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease
BioAge Labs NASDAQ: BIOA executives used a fireside chat at the Jefferies 2026 Global Healthcare Conference to outline the company's plans for BGE-102, its lead NLRP3 inhibitor, with near-term readouts expected in cardiovascular risk and diabetic macular edema.
BioAge Labs, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 57 | $253.46 | $492.31 | $238.85 | 94.24% |
| NA Nizar Araji National Bank Of Canada /FI/ | 125 | $2,658.91 | $1,465 | -$1,193.91 | -44.9% |
 Yiheng Capital Management Yiheng Capital Management LP | 170,532 | $4.18M | $1.62M | -$2.56M | -61.32% |
 Joseph Castro Nuveen LLC | 349,142 | $7.79M | $3.02M | -$4.77M | -61.25% |
 Regan O'Neill Burkehill Global Management LP | 100,000 | $1.75M | $959,000 | -$790,000 | -45.17% |
BioAge Labs, Inc. (BIOA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has BioAge Labs, Inc. ever had a stock split?
BioAge Labs, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Kristen Fortney CEO | NASDAQ (NGS) Exchange | 09077V100 CUSIP |
| US Country | 61 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
BioAge Labs, Inc. is a pioneering entity in the biopharmaceutical arena, distinguished for its focus on developing innovative therapeutic product candidates aimed at addressing metabolic disorders. Established in 2015 and operating from its headquarters in Richmond, California, BioAge Labs leverages a unique fusion of cutting-edge technology platforms and unparalleled human datasets. This distinctive approach empowers the company to pinpoint and target molecular alterations that propel the aging process, setting a new standard in the understanding and treatment of age-related diseases. The commitment to translating scientific discoveries into clinical solutions underscores BioAge Labs' role as a vanguard in the fight against aging and its associated conditions.
Products and Services
BioAge Labs' influential portfolio of products and services exemplifies its dedication to combatting aging and metabolic diseases through innovative therapeutics:
- Azelaprag
- BGE-100
A groundbreaking venture into the realm of obesity management, azelaprag stands out as an orally available small molecule presently undergoing a phase 1 clinical trial. Its development is part of BioAge Labs' focused efforts to address the complex challenges of obesity. Furthermore, the initiative has been expanded to include a phase 2 clinical trial where azelaprag is combined with tirzepatide, specifically targeting the treatment of obesity in older adults. This strategic approach embodies the company’s dedication to tailoring interventions that meet the nuanced needs of differing patient demographics.
A reflection of BioAge Labs' pioneering spirit and its commitment to leveraging cutting-edge science for health betterment, BGE-100 is an orally available, brain-penetrant small molecule. This NLRP3 antagonist is at the forefront of efforts to combat diseases driven by neuroinflammation, marking a significant stride towards tackling the intricate challenges of neurodegenerative disorders. Through the development of BGE-100, BioAge Labs reinforces its commitment to innovation and its role in paving new pathways in the treatment of diseases associated with aging and inflammation.
